Format

Send to

Choose Destination
Future Oncol. 2015;11(21):2923-36. doi: 10.2217/fon.15.239. Epub 2015 Sep 28.

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

Author information

1
Section of Gastroenterology - Di.Bi.M.I.S., University of Palermo, Palermo, Italy.
2
Unité Médicale de Transplantation Hépatique AP-HP, Hôpital Pitié-Salpêtrière, UPMC Paris, Paris, France.
3
Section of Radiology - Di.Bi.Me.F., University of Palermo, Palermo, Italy.
4
Section of Anesthesiology, Analgesia, Intensive Care & Emergency, Department of Biopathology, Medical & Forensic Biotechnologies (DIBIMEF), Policlinico 'P Giaccone', University of Palermo, Palermo, Italy.
5
Gastroenterology Unit, Cisanello Hospital, Pisa, Italy.

Abstract

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70-85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. The aim of this review is to underline the main concerns, pitfalls and warnings for these patients.

KEYWORDS:

hepatocellular carcinoma; immunosuppression; liver transplantation; living donors; recurrence

PMID:
26414336
DOI:
10.2217/fon.15.239
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center